2,3,4,5-tetrahydro-1H-3-benzazepines and CNS affecting use thereof

Abstract

Novel 2,3,4,5-tetrahydro-1H-3-benzazepines which in the 5-position have furyl, thienyl, pyridyl, or ring systems consisting of phenyl ortho condensed with a benzen, cyclohexan, cyclohexen, cyclopentan or cyclopenten ring wherein one of the carbon atoms may be exchanged with oxygen, sulphur or nitrogen, have interesting central nervous system and cardiovascular effects.

We claim: 
     
       1. 2,3,4,5-tetrahydro-1H-3-benzazepines of the general formula: ##STR5## R is H, R 2  is halogen, wherein R 7  is H or C 1-4  alkyl and R 5  is a ring system consisting of phenyl ortho condensed with a benzene, cyclohexane, cyclohexene, cyclopentane, or with a cyclopentene ring, which may be substituted with halogen, hydroxy or methoxy, or furan, dihydrofuran, dihydropyran or halogenated dihydropyran ring.   
     
     
       2. Benzazepines according to claim 1 wherein R 7  is H or methyl. 
     
     
       3. A benzazepine according to claim 2 wherein R 2  is chloro, R 5  is 7-benzofuranyl and R 7  is methyl. 
     
     
       4. Benzazepines, according to claim 1, wherein R 5  is benzofuranyl or 2,3-dihydrobenzofuranyl. 
     
     
       5. Benzazepines, according to claim 1, wherein R 5  is chromanyl or chromenyl. 
     
     
       6. Benzazepines, according to claim 1, wherein R 7  is hydrogen or methyl. 
     
     
       7. The benzazepine according to claim 1, 8-chloro-7-hydroxy-3-methyl-5- (2,3 dihydrobenzofuran - 7-yl) - 2,3,4,5, - tetrahydro -1H-3 benzazepine. 
     
     
       8. 2,3,4,5-tetrahydro-1H-3-benzazepines of the general formula: ##STR6## R is CH 3 , R 2  is halogen, wherein R 7  is H or C 1-4  alkyl and R 5  is a ring system consisting of phenyl ortho condensed with a benzene, cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring, which may be substituted with halogen, hydroxy or methoxy or with a furan, dihydrofuran, dihydropyran or halogenated dihydropyran ring.   
     
     
       9. A benzazepine according to claim 8 wherein R 2  is chloro, R 5  is 7-benzofuranyl and R 7  is methyl. 
     
     
       10. A benzazepine according to claim 8 wherein R 2  is chloro, R 5  is 2, 3-dihydrobenzofuran - 7-yl. 
     
     
       11. A pharmaceutical composition containing a benzazepine of the below-given formula or a physiologically acceptable salt thereof: ##STR7## wherein R 2  is halogen, R 7  is H or C 1-4  alkyl, and R 5  is a ring system consisting of phenyl ortho condensed with a benzene, cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring, which may be substituted with halogen, hydroxy, or methoxy, or with a furan, dihydrofuran, dihydropyran, or halogenated dihydropyran ring.   
     
     
       12. A pharamaceutical composition according to claim 11 containing between 0.07 mg and 70 mg of benzazepine per unit dosage. 
     
     
       13. A method for treating schizophrenia and manic-depressive disorders which comprises administering a pharmaceutically effective dosage of a benzazepine of the below-given formula or a physiologically acceptable salt thereof: ##STR8## wherein R 2  is halogen, R 7  is H or C 1-4  alkyl, and R 5  is a ring system consisting of phenyl ortho condensed with a benzene, cyclohexane, cyclohexene, cyyclopentane, or cyclopentene ring, which may be substituted with halogen, hydroxy or methoxy, or with a furan, dihydrofuran, dihydropyran, or halogenated dihydropyran ring.